These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 32416764)

  • 1. Tumour-specific fluorescence-guided surgery for pancreatic cancer using panitumumab-IRDye800CW: a phase 1 single-centre, open-label, single-arm, dose-escalation study.
    Lu G; van den Berg NS; Martin BA; Nishio N; Hart ZP; van Keulen S; Fakurnejad S; Chirita SU; Raymundo RC; Yi G; Zhou Q; Fisher GA; Rosenthal EL; Poultsides GA
    Lancet Gastroenterol Hepatol; 2020 Aug; 5(8):753-764. PubMed ID: 32416764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal Dosing Strategy for Fluorescence-Guided Surgery with Panitumumab-IRDye800CW in Head and Neck Cancer.
    Nishio N; van den Berg NS; van Keulen S; Martin BA; Fakurnejad S; Zhou Q; Lu G; Chirita SU; Kaplan MJ; Divi V; Colevas AD; Rosenthal EL
    Mol Imaging Biol; 2020 Feb; 22(1):156-164. PubMed ID: 31054001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular fluorescence-guided surgery of peritoneal carcinomatosis of colorectal origin: a single-centre feasibility study.
    Harlaar NJ; Koller M; de Jongh SJ; van Leeuwen BL; Hemmer PH; Kruijff S; van Ginkel RJ; Been LB; de Jong JS; Kats-Ugurlu G; Linssen MD; Jorritsma-Smit A; van Oosten M; Nagengast WB; Ntziachristos V; van Dam GM
    Lancet Gastroenterol Hepatol; 2016 Dec; 1(4):283-290. PubMed ID: 28404198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastatic and sentinel lymph node mapping using intravenously delivered Panitumumab-IRDye800CW.
    Krishnan G; van den Berg NS; Nishio N; Juniper G; Pei J; Zhou Q; Lu G; Lee YJ; Ramos K; Iagaru AH; Baik FM; Colevas AD; Martin BA; Rosenthal EL
    Theranostics; 2021; 11(15):7188-7198. PubMed ID: 34158844
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers.
    Gao RW; Teraphongphom N; de Boer E; van den Berg NS; Divi V; Kaplan MJ; Oberhelman NJ; Hong SS; Capes E; Colevas AD; Warram JM; Rosenthal EL
    Theranostics; 2018; 8(9):2488-2495. PubMed ID: 29721094
    [No Abstract]   [Full Text] [Related]  

  • 6. Panitumumab-IRDye800CW for Fluorescence-Guided Surgical Resection of Colorectal Cancer.
    Marston JC; Kennedy GD; Lapi SE; Hartman YE; Richardson MT; Modi HM; Warram JM
    J Surg Res; 2019 Jul; 239():44-51. PubMed ID: 30798171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Formalin Fixation for Near-Infrared Fluorescence Imaging with an Antibody-Dye Conjugate in Head and Neck Cancer Patients.
    Kapoor S; Lu G; van den Berg NS; Krishnan G; Pei J; Zhou Q; Martin BA; Baik FM; Rosenthal EL; Nishio N
    Mol Imaging Biol; 2021 Apr; 23(2):270-276. PubMed ID: 33078373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Sentinel Margin: Intraoperative
    van Keulen S; Nishio N; Birkeland A; Fakurnejad S; Martin B; Forouzanfar T; Cunanan K; Colevas AD; S van den Berg N; Rosenthal E
    Clin Cancer Res; 2019 Aug; 25(15):4656-4662. PubMed ID: 31142505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity and Specificity of Cetuximab-IRDye800CW to Identify Regional Metastatic Disease in Head and Neck Cancer.
    Rosenthal EL; Moore LS; Tipirneni K; de Boer E; Stevens TM; Hartman YE; Carroll WR; Zinn KR; Warram JM
    Clin Cancer Res; 2017 Aug; 23(16):4744-4752. PubMed ID: 28446503
    [No Abstract]   [Full Text] [Related]  

  • 10. Intraoperative Molecular Fluorescence Imaging of Pancreatic Cancer by Targeting Vascular Endothelial Growth Factor: A Multicenter Feasibility Dose-Escalation Study.
    Mulder BGS; Koller M; Duiker EW; Sarasqueta AF; Burggraaf J; Meijer VE; Vahrmeijer AL; Hoogwater FJH; Bonsing BA; van Dam GM; Mieog JSD; Pranger BK
    J Nucl Med; 2023 Jan; 64(1):82-89. PubMed ID: 35680414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and effectiveness of SGM-101, a fluorescent antibody targeting carcinoembryonic antigen, for intraoperative detection of colorectal cancer: a dose-escalation pilot study.
    Boogerd LSF; Hoogstins CES; Schaap DP; Kusters M; Handgraaf HJM; van der Valk MJM; Hilling DE; Holman FA; Peeters KCMJ; Mieog JSD; van de Velde CJH; Farina-Sarasqueta A; van Lijnschoten I; Framery B; Pèlegrin A; Gutowski M; Nienhuijs SW; de Hingh IHJT; Nieuwenhuijzen GAP; Rutten HJT; Cailler F; Burggraaf J; Vahrmeijer AL
    Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):181-191. PubMed ID: 29361435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.
    Nywening TM; Wang-Gillam A; Sanford DE; Belt BA; Panni RZ; Cusworth BM; Toriola AT; Nieman RK; Worley LA; Yano M; Fowler KJ; Lockhart AC; Suresh R; Tan BR; Lim KH; Fields RC; Strasberg SM; Hawkins WG; DeNardo DG; Goedegebuure SP; Linehan DC
    Lancet Oncol; 2016 May; 17(5):651-62. PubMed ID: 27055731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorescence-guided imaging for resection margin evaluation in head and neck cancer patients using cetuximab-800CW: A quantitative dose-escalation study.
    Voskuil FJ; de Jongh SJ; Hooghiemstra WTR; Linssen MD; Steinkamp PJ; de Visscher SAHJ; Schepman KP; Elias SG; Meersma GJ; Jonker PKC; Doff JJ; Jorritsma-Smit A; Nagengast WB; van der Vegt B; Robinson DJ; van Dam GM; Witjes MJH
    Theranostics; 2020; 10(9):3994-4005. PubMed ID: 32226534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.
    Alistar A; Morris BB; Desnoyer R; Klepin HD; Hosseinzadeh K; Clark C; Cameron A; Leyendecker J; D'Agostino R; Topaloglu U; Boteju LW; Boteju AR; Shorr R; Zachar Z; Bingham PM; Ahmed T; Crane S; Shah R; Migliano JJ; Pardee TS; Miller L; Hawkins G; Jin G; Zhang W; Pasche B
    Lancet Oncol; 2017 Jun; 18(6):770-778. PubMed ID: 28495639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.
    Marron TU; Fiel MI; Hamon P; Fiaschi N; Kim E; Ward SC; Zhao Z; Kim J; Kennedy P; Gunasekaran G; Tabrizian P; Doroshow D; Legg M; Hammad A; Magen A; Kamphorst AO; Shareef M; Gupta NT; Deering R; Wang W; Wang F; Thanigaimani P; Mani J; Troncoso L; Tabachnikova A; Chang C; Akturk G; Buckup M; Hamel S; Ioannou G; Hennequin C; Jamal H; Brown H; Bonaccorso A; Labow D; Sarpel U; Rosenbloom T; Sung MW; Kou B; Li S; Jankovic V; James N; Hamon SC; Cheung HK; Sims JS; Miller E; Bhardwaj N; Thurston G; Lowy I; Gnjatic S; Taouli B; Schwartz ME; Merad M
    Lancet Gastroenterol Hepatol; 2022 Mar; 7(3):219-229. PubMed ID: 35065058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR-targeted intraoperative fluorescence imaging detects high-grade glioma with panitumumab-IRDye800 in a phase 1 clinical trial.
    Zhou Q; van den Berg NS; Rosenthal EL; Iv M; Zhang M; Vega Leonel JCM; Walters S; Nishio N; Granucci M; Raymundo R; Yi G; Vogel H; Cayrol R; Lee YJ; Lu G; Hom M; Kang W; Hayden Gephart M; Recht L; Nagpal S; Thomas R; Patel C; Grant GA; Li G
    Theranostics; 2021; 11(15):7130-7143. PubMed ID: 34158840
    [No Abstract]   [Full Text] [Related]  

  • 17. Fluorescence- and multispectral optoacoustic imaging for an optimized detection of deeply located tumors in an orthotopic mouse model of pancreatic carcinoma.
    Napp J; Stammes MA; Claussen J; Prevoo HAJM; Sier CFM; Hoeben FJM; Robillard MS; Vahrmeijer AL; Devling T; Chan AB; de Geus-Oei LF; Alves F
    Int J Cancer; 2018 May; 142(10):2118-2129. PubMed ID: 29277891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of Tumor Margins with Surgical Specimen Mapping Using Near-Infrared Fluorescence.
    Gao RW; Teraphongphom NT; van den Berg NS; Martin BA; Oberhelman NJ; Divi V; Kaplan MJ; Hong SS; Lu G; Ertsey R; Tummers WSFJ; Gomez AJ; Holsinger FC; Kong CS; Colevas AD; Warram JM; Rosenthal EL
    Cancer Res; 2018 Sep; 78(17):5144-5154. PubMed ID: 29967260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
    Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
    Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
    Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
    Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.